Catalysts in Science

Fifteen years after the HIV Prevention Trials Network (HPTN) 052 study changed the understanding of HIV transmission, its influence continues to extend far beyond the clinic. In this conversation, Jared Baeten of Gilead reflects on how the landmark study gave rise to Undetectable = Untransmittable, where according to this research, taking HIV treatment as prescribed and getting to and staying undetectable, prevents sexual transmission of HIV, helping reduce stigma while reshaping HIV care.

He also discusses why the next phase of innovation will depend on listening to patients, expanding access to care, and developing new treatment and prevention options that meet people where they are.

Listen: https://www.statnews.com/sponsor/2026/07/23/fifteen-years-later-uu-continues-to-shape-hiv-care/

Advances in oncology are creating new opportunities to deliver more personalized care for patients.

In this sponsored conversation, Dr. Mika Kakefuda Derynck, Senior Vice President and Therapeutic Area Head of Oncology at Gilead Sciences, and Dr. Gallia Levy, Senior Vice President and Global Head of Development at Kite, discuss the future of cancer treatment, including antibody-drug conjugates (ADCs), CAR-T cell therapies, patient-centered clinical trial design, and efforts to improve access to innovative treatments.

Moderated by Terzel Vasquez.

Read more: https://www.statnews.com/sponsor/2026/06/25/new-approaches-for-cancers-toughest-challenges/

Oncology leaders Jackson Egen of Gilead Sciences and Priti

Moderated by Jesse McQuarters.

Read more: https://www.statnews.com/sponsor/2026/04/16/how-unmet-patient-needs-are-shaping-the-next-phase-of-cancer-research/

Image credit: Radhika Patnala/Endosymbiont GmBH

Drug pricing reforms were meant to protect patients — but they may also be reshaping where innovation happens. In this interview, John Stanford of Incubate explains how MFN price controls and regulatory uncertainty ripple through the biotech ecosystem, squeezing small innovators and pushing investment abroad. Moderated by Terzel Vasquez, Producer, STAT Brand Studio.

Read more: https://www.statnews.com/sponsor/2026/03/04/could-u-s-policy-clinch-chinas-grip-on-biotech/

At the 2026 JPM Conference in San Francisco, Astellas President and CEO Naoki Okamura spoke with STAT Brand Studio Editor Jesse McQuarters about the company’s strategy and long-term vision as it enters an important phase in the company’s evolution. Astellas is taking a patient-centered approach and investing in four key areas within R&D — targeted protein degradation, immuno-oncology, blindness and regeneration, and genetic regulation — as it prepares for the loss of exclusivity of its leading prostate cancer therapy.

Read more here: https://www.statnews.com/sponsor/2026/02/23/astellas-ceo-talks-transformative-medicines-driving-growth/

People living with asthma understand that their environment affects their health, but they’re often left without the tools, guidance, or support to fully act on that knowledge. In this virtual event, Chiesi unveils findings from its recent Asthma Community Survey, which looks at this fundamental gap and potential solutions.

In particular, this conversation explores how embedding Environmental Health Literacy (EHL) into clinical, community, and digital systems can help individuals navigate air quality improvements with greater confidence, and panelists lay out a roadmap for building more responsive, patient-centered asthma care.

• Anju T. Peters, M.D. M.SCI, Professor of Medicine, Director of Clinical Research, Division of Allergy and Immunology, Director, Center for Clinical Research, Northwestern University Clinical and Translational, Sciences Institute (NUCATS), Medical Director, Northwestern Medicine Clinical Research Unit, Northwestern University Feinberg School of Medicine

• Cindy Trubisky, M.Ed., AE-C, Senior Director, Nationwide Health Promotions, Asthma Programs, American Lung Association

• Jesse McQuarters, Editor, STAT Brand Studio

Read more: https://www.statnews.com/sponsor/2025/12/01/do-enough-allergists-and-pcps-know-about-environmental-health-literacy/

In this collaborative episode of The Nucleus, Dr. John Overton, vice president and chief sequencing officer at Regeneron Genetics Center (RGC), joins STAT Brand Studio’s Jesse McQuarters to explore how integrating proteomics and multi-omics can deliver deeper insight into how diseases develop — and how science can better predict and prevent them.

Read more: https://www.statnews.com/sponsor/2025/10/09/taking-possibility-back-across-oncologys-toughest-frontiers/

Photo: Radhika Patnala/Endosymbiont GmBH

Biosimilars are driving down drug costs, expanding access to critical treatments, and creating space for future innovation. In this episode, Linda Choi MacDonald, EVP and Global Head of Commercial at Samsung Bioepis, discusses the challenges slowing biosimilar development — and how policy reforms, stronger incentives, and provider education can help close the gap.

Read more: https://www.statnews.com/sponsor/2025/09/18/can-provider-education-and-smarter-policy-close-the-biosimilars-gap/

The sudden passing of Dr. Stephen Harrison in 2024 marked the loss of a

Read more: https://www.statnews.com/sponsor/2025/08/25/empowering-patients-to-shape-the-future-of-mash-care/↗

Wayne Eskridge — Founder and CEO, Fatty Liver Foundation

Dr. Maru Rinella — Professor of Medicine and Director, Metabolic and Fatty Liver Disease program, University of Chicago

Dr. Becky Taub — Founder and Senior Scientific & Medical Advisor, Madrigal Pharmaceuticals

Moderator:

Jesse McQuarters — Editor, STAT Brand Studio